

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (currently amended) An isolated RNase A superfamily polypeptide having an N-terminus of the sequence: X<sup>1</sup>X<sup>2</sup>SLX<sup>3</sup>V (SEQ ID NO:9), wherein X<sup>1</sup> represents methionine ~~or is absent~~, X<sup>2</sup> represents glycine or is absent, and X<sup>3</sup> represents ~~an~~ any amino acid residue (~~SEQ ID NO:9~~), said RNase A superfamily polypeptide being selectively toxic to a proliferating endothelial cell.
2. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 having SEQ ID NO:2.
3. (canceled)
4. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 having SEQ ID NO:4.
5. (canceled)
6. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 wherein the N-terminus is MSLHV (SEQ ID NO:11).
7. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 wherein the N-terminus is MGSLHV (SEQ ID NO:10).
8. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 wherein the N-terminus is attached to the eosinophil derived neurotoxin (EDN) protein.
9. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 wherein the proliferating endothelial cell is a neoplastic endothelial cell.

10. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 wherein the proliferating endothelial cell is a non-neoplastic endothelial cell.

11. (currently amended) An isolated RNase A superfamily polypeptide of claim 9 wherein the neoplastic endothelial cell is a Kaposi sarcoma KS Y-1 cell.

12. (currently amended) An isolated RNase A superfamily polypeptide of claim 9 wherein the neoplastic endothelial cell is a KS Y-3 cell.

13. (currently amended) An isolated RNase A superfamily polypeptide of claim 9 wherein the neoplastic endothelial cell is selected from the group consisting of KS 1, KS 2, KS 3, KS 4, KS 5, and KS 6 cells.

14. (currently amended) A pharmaceutical composition comprising

- a. a unit dosage RNase A superfamily polypeptide comprising an N-terminus of the sequence:  $X^1X^2SLX^3V$  (SEQ ID NO:9), wherein  $X^1$  represents methionine ~~or is absent~~,  $X^2$  represents glycine or is absent, and  $X^3$  represents ~~an~~ any amino acid residue (~~SEQ ID NO:9~~), said RNase A superfamily polypeptide being selectively toxic to a proliferating endothelial cell; and
- b. a pharmaceutically acceptable carrier.

15-21. (canceled)